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INTRODUCTION
The number of endoscopic procedures has increased con-
siderably due to the wide use of screening upper and lower en-
doscopy. The complexity of endoscopic procedures has also 
increased due to the wide adoption of interventional tech-
niques such as endoscopic submucosal dissection and peroral 
endoscopic myotomy. More advanced techniques have in turn 
increased the need of sedation.1 The use of propofol for seda-
tion during endoscopic procedures has increased in recent 
years,2 mainly because of its favorable pharmacokinetic profile 
compared with traditional endoscopy sedation drugs such as 
benzodiazepines and opioids.3,4 Propofol (2,6-diisopropyl-phe-
nol) is a phenolic derivative with satisfactory sedative, hypnot-
ic, antiemetic, and amnesic properties. Propofol is highly lipo-
philic and thus can rapidly cross the blood-brain barrier, 
resulting in an early onset of action (the drug can induce un-
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consciousness within periods as short as 30 seconds).5 The 
depth of sedation increases in a dose-dependent manner. As 
an additional advantage, regardless of the depth or length of 
the sedation period, propofol has a short recovery profile (re-
covery occurs within 10 to 20 minutes after discontinuation).5 
Propofol has a short half-life (4 minutes vs. 30 minutes for 
midazolam).5,6 With regard to side effects, although propofol is 
generally associated with good hemodynamic stability, it can 
induce a dose-dependent decrease in blood pressure and heart 
rate. To date, no pharmacological antagonist has been devel-
oped.
In the United States, propofol is generally administered by 
anesthesia specialists, despite the evidence that endoscopists 
can administer or supervise the administration of propofol 
safely without the involvement of an anesthesia specialist.7-12 
The administration of propofol by anesthesia specialists for 
routine endoscopic procedures is controversial because it adds 
significantly to the cost of endoscopic procedures without an 
established improvement in outcomes.13 On the other hand, 
the administration of propofol by endoscopists or supervision 
of its administration by endoscopists is controversial because 
anesthesiologists claim that it is unsafe.14 Concerns about the 
safety of endoscopist-directed propofol (EDP) have been voiced 
that propofol should be given only by healthcare professionals 
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trained in the administration of general anesthesia.14 Here we 
discuss about the safety and drawbacks of EDP for routine en-
doscopic procedures.
DEFINITION OF SEDATION
According to the American Society of Anesthesiologists 
(ASA), sedation and analgesia comprise a continuum of states 
ranging from minimal sedation (anxiolysis) through general 
anesthesia.15 It is important to recognize this continuum as 
summarized in Table 1. A change in the level of sedation from 
conscious sedation to general anesthesia may occur inadver-
tently with a relatively small alteration in the dose of sedative 
drugs used.16
SIDE EFFECTS OF PROPOFOL
Propofol possesses relatively little analgesic effect, and its 
amnesic effect is less pronounced than that of midazolam.7,10 
Local pain occurs in 30% of patients during administration of 
propofol. This can lead to a fall in systemic vascular resistance 
and cardiac contractility and consequent hypotension.17 Pro-
pofol can reduce cardiac output without a concomitant change 
in heart rate.18,19 Respiratory depression can also occur with 
propofol use. Slow administration of propofol boluses has not 
been shown to attenuate these cardiorespiratory effects al-
though using propofol as an infusion may do this.
Propofol can also give rise to myoclonic jerks and convul-
sions; these are usually very transient and occur as the sedative 
effects of propofol are wearing off.20,21 The metabolism of pro-
pofol is different in the elderly and the dose should be reduced 
in these patients. Impaired cardiac function also potentiates 
the effects of propofol but impaired renal or hepatic function 
does not affect propofol activity to a significant extent.21 In pa-
tients with cirrhosis, use of propofol for elective upper endos-
copy does not precipitate encephalopathy.21
SAFETY OF ENDOSCOPIST-DIRECTED 
PROPOFOL
The method of choice for safe administration of propofol is 
by intermittent bolus. Safety literature has been developed pri-
marily in the United States, Switzerland, and Japan (Table 2).1-30 
In the United States, EDP has been restricted largely to the 
states without nursing practice acts or laws prohibiting propo-
fol administration by nonanesthesiologists. The largest volume 
of data has been collected by Heuss et al.11 and Kulling et al.31 
in Switzerland, Tohda et al.32 in Japan, Walker’s group in Med-
ford, Oregon, and the group at Indiana University Hospital in 
the United States.20
Heuss et al.11 reported that the administration of propofol 
under the supervision of the gastroenterologist is safe for con-
scious sedation during endoscopic procedures. They observed 
82,620 endoscopic procedures and there were no severe ad-
verse effects.11 Cohen et al.22 reported that propofol could be 
safely and effectively administered under the direction of a 
gastroenterologist. They observed 638 colonoscopies and 181 
upper endoscopies. Hypotension (>20 mm Hg decline in ei-
ther systolic or diastolic blood pressure) developed in 218 pa-
tients (27%), and hypoxemia (oxygen saturation <90%) oc-
curred in 75 patients (9%).22 All episodes of hypotension and 
hypoxemia were transient, and there was no need of assisted 
ventilations. Rex et al.,14 in a safety review of 646,080 EDP se-
dation cases (223,656 published and 422,424 unpublished), 
noted that endotracheal intubation and death occurred in 11 
and 4 cases, respectively. There were no patients with perma-
nent neurologic sequelae, although one patient had a tonic-
clonic seizure, and one had a transient ischemic attack 
(blindness), both of which resolved without sequelae.14 They 
concluded that EDP appears to result in a lower mortality 
rate than traditional sedation with benzodiazepines and opi-
oids, and to have a comparable rate to that of general anesthe-
sia administered by anesthesiologists.14 The four deaths ob-
served after EDP administration occurred in patients with 
ASA III or higher who were undergoing nonroutine medical 
procedures.14 Three of the patients had serious underlying 
medical conditions. The results suggest that such patients 
should be sedated by an anesthesiologist; however, nonanes-
thesiologists have successfully used propofol for patients with 
higher ASA classes, despite the higher risk associated with se-
dating these patients.
The current controversy surrounding performance of EDP 
and the cost of anesthesia specialists for endoscopy are focused 
on average-risk patients undergoing routine procedures. Pa-
tient factors almost certainly contributed to the reported 
deaths. Anesthesiologist-administered propofol for truly rou-
tine procedures in average-risk patients would be very costly 
and may be unjustified, because there were no deaths or per-
manent sequelae among such patients or procedures.
AN ALTERNATIVE METHOD FOR  
REDUCING THE SIDE EFFECTS OF  
PROPOFOL: BALANCED PROPOFOL 
SEDATION
Combining propofol with an additional drug (benzodiaze-
pine/opioid/ketamine) allows the dose of propofol adminis-
tered to be reduced without reproducible effect on recovery 
time.33,34 Administration of ‘balanced propofol sedation’ seems 
to be associated with less need for assisted ventilation, al-
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though this has not been demonstrated in head-to-head com-
parisons. It is clear, however, just from an observational stand-
point, that balanced propofol sedation allows more moderate 
levels of sedation compared with single-agent propofol.1,7 Dur-
ing upper endoscopy, single-agent propofol titrated only to 
moderate sedation is frequently accompanied by coughing 
and gagging.7 These responses during upper endoscopy tend 
to cause endoscopists to administer additional propofol to 
drive patients into deep sedation. Although this has been re-
ported safe in the literature, the need for mask ventilation 
seems to be greater when single-agent propofol is used. Bal-
anced propofol sedation, or combination therapy, has several 
Table 1. Depth of Sedation
Responsiveness Airway Spontaneous ventilation Cardiovascular function
Minimal Normal to verbal stimulation Unaffected Unaffected Unaffected
Moderate Purposeful response 
  to verbal or tactile stimulation
No intervention required Adequate Usually maintained
Deep Purposeful response after 
  repeated or painful stimulation
Intervention may be required May be inadequate Usually maintained
General
  anesthesia
Unrousable even with 
  painful stimulation
Intervention often required Frequently inadequate May be impaired
Table 2. References to Endoscopist-Directed Propofol Sedation in the Literature
Country
Administration 
of propofol
Dose of propofol, 
mean (range), mg
Endoscopic 
procedure (n)
No. 
of procedures
Kulling et al. (2007)31 Switzerland IV bolus EGD 161 (50–650)
Colonoscopy 116 (30–500)
EGD (14,856)
Colonoscopy (12,205)
27,061
Kulling et al. (2003)9 Switzerland IV bolus EGD 180 (60–400)
Colonoscopy 157 (70–340)
EGD (161)
Colonoscopy (139)
300
Vargo et al. (2002)7 United States IV bolus 536.8 ERCP (29)
EUS (9)
38
Sipe et al. (2007)40 United States IV bolus 90 (50–130) Colonoscopy (100) 100
Tagle et al. (2007)41 Peru IV bolus 85.6 (10–330) EGD (85)
Colonoscopy (315)
400
Tohda et al. (2006)32 Japan IV bolus EGD 72 (20–150)
Colonoscopy 94 (40–190)
EGD (19,600)
Colonoscopy (7,900)
27,500
Tohda et al. (2006)24 Japan IV bolus EGD 74 (40–160) EGD (120) 120
Cohen et al. (2004)10 United States IV bolus EGD 79 (10–190)
Colonoscopy 98 (30–250)
EGD (26)
Colonoscopy (74)
100
Cohen et al. (2003)22 United States IV bolus EGD 52 (10–150)
Colonoscopy 66 (5–230)
EGD (181)
Colonoscopy (638)
819
Saenz-Lopez et al. (2006)42 Spain IV bolus EGD 72.1 (20–200)
Colonoscopy 71.3 (20–200)
EGD (42)
Colonoscopy (60)
102
Riphaus et al. (2005)43 Germany IV bolus ERCP 322 (40–900) ERCP (75) 75
Wehrmann et al. (2002)44 Germany IV infusion ERCP 360 (90–920) ERCP (40) 40
Yusoff et al. (2004)45 Canada IV bolus
→IV infusion
ERCP 301 (100–1,000) EUS (300) 300
Koshy et al. (2000)46 United States IV bolus 40 (20–120) EGD (78)
Colonoscopy (72)
150
Clarke et al. (2002)8 Australia IV bolus EGD 25 (5–120)
Colonoscopy 60 (10–220)
EGD (13,204)
Colonoscopy (15,268)
28,472
Morse et al. (2008)47 Canada IV bolus EGD 167.9
Colonoscopy 226.9
EGD+colonoscopy 291.6
EGD (296)
Colonoscopy (296)
EGD+colonoscopy (88)
680
IV, intravenous; EGD, esophagogastroduodenoscopy; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound.
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distinct advantages for EDP.5,7,32
First, it maintains a reversible drug component, because an-
tagonists to both opioids and benzodiazepines are available. 
Second, it simplifies the administration of propofol, because 
even low doses of an opioid or a benzodiazepine result in re-
duction of the total dose of propofol by more than 50%. Third, 
administration of propofol is smoother because boluses are 
not only smaller but also given less often. Prospective studies 
have indicated that the actual incidence of deep sedation us-
ing balanced propofol sedation targeted to moderate levels is 
lower than when opioids and benzodiazepines are used with-
out propofol.15,35 A randomized controlled trial in which sin-
gle-agent propofol titrated to deep sedation was compared 
with balanced propofol sedation (targeted to moderate seda-
tion) using fentanyl and propofol, midazolam and propofol, or 
fentanyl, midazolam, and propofol showed that the combina-
tion regimens could be successfully targeted to moderate seda-
tion and that satisfaction was kept at a high level compared 
with single-agent propofol, with no lengthening of the time for 
recovery.1,5,36 In fact, patients who received combination thera-
py actually recovered faster than those who received single-
agent propofol, presumably because they were recovering 
from only moderate sedation.
INTERMITTENT BOLUS INJECTION 
VERSUS CONTINUOUS INFUSION OF 
PROPOFOL
Continuous propofol-infusion is an alternative procedure 
for deep sedation with intermittent bolus application of propo-
fol. Continuous infusion of propofol may be theoretically as-
sociated with a less need for user interventions, maintenance 
of a more consistent level of sedation, and probably a lower to-
tal drug dose required. Additionally, the avoidance of high 
peak propofol plasma concentrations, which occurred during 
bolus application, may reduce the intensity of the hypotensive 
effect of propofol. Furthermore, a rapid lightening of the seda-
tive effect with subsequent patient movements may be avoided 
by only minimal fluctuations of the plasma propofol concen-
tration under continuous infusion.
However, according to reported studies, continuous infu-
sion of propofol holds no relevant advantages. Neither the total 
dose of propofol required nor the sedation efficacy or the fre-
quency of side effects are improved by infusion versus bolus 
administration. Bennett et al.37 compared incremental bolus 
with continuous infusion of propofol for deep sedation during 
dentoalveolar surgery after induction with a bolus of mid-
azolam/fentanyl, and found no significant differences in effi-
ciency, safety, and recovery. However, in the continuous infu-
sion group, a statistically higher maintenance dose of propofol 
(7.3 mg/kg/hr vs. 6.03 mg/kg/hr, p<0.05) was needed to main-
tain anesthesia.37 In a study by Klein et al.,38 18 children who 
underwent 40 elective oncology procedures were randomly 
assigned to intermittent bolus administration or continuous 
propofol infusion. Adequate sedation and examiner satisfac-
tion were comparable between the two groups.38 Riphaus et 
al.39 reported no difference in total propofol dose between the 
bolus group and the infusion group. Arterial blood pressure 
<90 mm Hg was documented in two patients in the bolus 
group and 7 patients in the infusion group (p=0.16).39 Recov-
ery time was significantly shorter in the bolus group compared 
with the infusion group (19±5 minutes vs. 23±6 minutes, 
p<0.001) whereas the quality of recovery was identical in the 
two groups.39
Repeated bolus administration as well as continuous infu-
sion of propofol allow nearly identical good controllability of 
endoscopic sedation and are associated with similar sedation 
efficacy and patient’s safety. However, the patient’s recovery 
time under continuous sedation is significantly slower and hy-
potension tends to occur more often. Therefore, repeated bo-
lus administrations of propofol might be more helpful at rou-
tine upper endoscopy.
CONCLUSIONS
Currently, both diagnostic and therapeutic endoscopy are 
well tolerated and accepted by both patients and endoscopists 
due to the implementation of sedation in most clinics world-
wide. Accordingly, propofol use is increasing in many coun-
tries. It is crucial for endoscopists to be very familiar with the 
use of propofol or a combination of drugs. However, the con-
troversy regarding the administration of sedation by an endos-
copist or an anesthesiologist continues. Until now, there have 
been no randomized control trials comparing propofol-in-
duced sedation administered by an endoscopist or by an anes-
thesiologist. It would be difficult to perform this kind of study. 
Currently, most of sedation drugs are administered during en-
doscopy by an endoscopist. However, a few death cases are re-
ported every year in Korea. EDP is a trend that cannot be gone 
against, but proper monitoring and familiarity with the ad-
verse events are needed. For the convenience and safety of 
sedative endoscopy, it would be important that EDP be gener-
ally applied to endoscopic procedures, and for more safety, an 
anesthesiologist may automatically take care of particular pa-
tients at high risk of suffering from propofol side effects.
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